Overview

A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer

Status:
Recruiting

Trial end date:
2027-05-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to establish the maximum tolerable dose of niraparib when combined with prostate stereotactic body radiotherapy (SBRT), abiraterone, leuprolide, and prednisone (the phase 1 portion of the study) and determine 3-year biochemical PSA recurrence free-survival with this treatment approach (the phase 2 portion of the study).

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

University of Michigan Rogel Cancer Center

Collaborator:

Janssen Scientific Affairs, LLC

Treatments:

Abiraterone Acetate
Androgens
Leuprolide
Niraparib